Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

摘要: Germinal center (GC) and non-GC phenotypes are predictors of outcome in diffuse large B-cell lymphoma (DLBCL) can be used to stratify chemotherapy-treated patients into low- high-risk groups. To determine how combination rituximab with chemotherapy influences GC-associated clinical outcome, GC were identified immunohistochemically from samples 90 de novo DLBCL treated CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)–like regimen (immunochemotherapy). One hundred four previously served as a control group. Consistent previous studies, defined phenotype displayed significantly better overall (OS) failure-free survival (FFS) than the group (OS, 70% vs 47%, P = .012; FFS, 59% 30%, .001). In contrast, did not predict immunochemotherapy-treated 77% 76%, ns; 68% 63%, ns). comparison, International Prognostic Index (IPI) could separate intermediate-risk groups 84% .030; 79% 52%, .028). We conclude that seems eliminate prognostic value GC- DLBCL.